Market Overview

Cramer's Cautious Take On Cannabis Stocks: 'Your Gains Could Go Up In Smoke'

Share:
Cramer's Cautious Take On Cannabis Stocks: 'Your Gains Could Go Up In Smoke'

Just two years ago it would have been impossible to imagine a Procter & Gamble Co (NYSE: PG) executive taking the helm of a cannabis company, but this is the new reality, according to CNBC's Jim Cramer.

What Happened

Brian Athaide, a 25-year veteran of the "most mainstream company on earth," was named CEO of The Green Organic Dutchman Holdings in early July. It's difficult to "explain how incongruous this is," but it also signals the "normalization of weed is happening so fast," Cramer said during his daily "Mad Money" show Friday.

Why It's Important

Athaide told Cramer at Friday's Green Market Report cannabis conference that the opportunity to lead the company was "just too great" ahead of the full legalization of recreational marijuana in Canada Oct. 17.

The date won't necessarily translate to a surge in profits for cannabis companies. Athaide said. The Canadian cannabis industry lacks the necessary infrastructure to sell cannabis products legally — even if the demand is there in the first place, he said. 

While cautioning investors not to "believe all the hype" around cannabis stocks, the CNBC host said his favorite pick remains Canopy Growth Corp (NYSE: CGC) due to its partnership with Constellation Brands, Inc. (NYSE: STZ).

What's Next

"Don't get ahead of yourself with the cannabis cohort or your gains could go up in smoke," Cramer said. "So pay close attention, dabble if you want."

Related Links:

2 Beverage Companies Jim Cramer Says Aren't Getting Enough Recognition

Jim Cramer Gives His Opinion On Tilray And Snap

Screenshot courtesy of CNBC. 

Posted-In: Canada Jim Cramer Mad MoneyCannabis Markets Media Best of Benzinga

 

Related Articles (PG + CGC)

View Comments and Join the Discussion!

BMO Shifts To Neutral Stance On Hormel, Cites Valuation, Trade Concerns

Mid-Morning Market Update: Markets Mostly Lower; Teva's Preventive Migraine Treatment Approved By FDA